These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 1723812)

  • 1. A patient weighted symptom score system in the evaluation of uncomplicated benign prostatic hyperplasia.
    Hald T; Nordling J; Andersen JT; Bilde T; Meyhoff HH; Walter S
    Scand J Urol Nephrol Suppl; 1991; 138():59-62. PubMed ID: 1723812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new patient weighted symptom score system (DAN-PSS-1). Clinical assessment of indications and outcomes of transurethral prostatectomy for uncomplicated benign prostatic hyperplasia.
    Meyhoff HH; Hald T; Nordling J; Andersen JT; Bilde T; Walter S
    Scand J Urol Nephrol; 1993; 27(4):493-9. PubMed ID: 7512748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
    Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
    BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of sexual function in men with symptomatic benign prostatic hyperplasia].
    Shao Q; Song J; Guo YW; Lu WC; Du LD
    Zhonghua Nan Ke Xue; 2005 Jul; 11(7):505-7. PubMed ID: 16078666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
    J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
    Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
    J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Validation of the patient-administered Danish Prostate Symptom Score Schedule].
    Hansen BJ; Flyger HL; Brasso K; Schou J; Nordling J; Andersen JT; Mortensen SO; Meyhoff HH; Walter S; Hald T
    Ugeskr Laeger; 1997 Jan; 159(5):591-7. PubMed ID: 9045449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study.
    Flanigan RC; Reda DJ; Wasson JH; Anderson RJ; Abdellatif M; Bruskewitz RC
    J Urol; 1998 Jul; 160(1):12-6; discussion 16-7. PubMed ID: 9628595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of the IPSS (International Prostate Symptoms Score) to evaluate the frequency of disability induced by each of the 7 symptoms. (CTMH-AFU study)].
    de la Taille A; Desgrandchamps F; Haillot O; Saussine C; Lukacs B; Marc F;
    Prog Urol; 2006 Nov; 16(5):568-71. PubMed ID: 17175953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
    Roehrborn CG; McVary KT; Elion-Mboussa A; Viktrup L
    J Urol; 2008 Oct; 180(4):1228-34. PubMed ID: 18722631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
    Bozlu M; Ulusoy E; Cayan S; Akbay E; Görür S; Akbay E
    Scand J Urol Nephrol; 2004; 38(5):391-5. PubMed ID: 15764250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of symptoms in patients with benign prostatic hyperplasia].
    Riehmann M; Jønler M; Nordling J; Hald T
    Ugeskr Laeger; 1996 May; 158(20):2853-8. PubMed ID: 8686021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.
    Suzuki H; Yano M; Awa Y; Nakatsu H; Egoshi K; Mikami K; Ota S; Okano T; Hamano S; Ohki T; Furuya Y; Ichikawa T
    Int J Urol; 2006 Sep; 13(9):1202-6. PubMed ID: 16984553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysfunctional voiding and incontinence scoring system: quantitative evaluation of incontinence symptoms in pediatric population.
    Akbal C; Genc Y; Burgu B; Ozden E; Tekgul S
    J Urol; 2005 Mar; 173(3):969-73. PubMed ID: 15711352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of symptoms in patients with benign prostatic hyperplasia].
    Cornu JN; Rouprêt M
    Prog Urol; 2007 Sep; 17(5 Suppl 1):1023-5. PubMed ID: 17969783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Quality of life assessment of the male with benign prostate hypertrophy].
    Nekić VC; Tiljak H; Petricek G; Soldo D; Nekić G; Buljan N
    Acta Med Croatica; 2007 Feb; 61(1):49-55. PubMed ID: 17593641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.
    Li MK; Garcia L; Patron N; Moh LC; Sundram M; Leungwattanakij S; Pripatnanont C; Cheng C; Chi-Wai M; Loi-Cheong N
    BJU Int; 2008 Jan; 101(2):197-202. PubMed ID: 18005205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function: a prospective study.
    Arai Y; Aoki Y; Okubo K; Maeda H; Terada N; Matsuta Y; Maekawa S; Ogura K
    J Urol; 2000 Oct; 164(4):1206-11. PubMed ID: 10992367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of nocturia in the International Prostate Symptom Score for benign prostatic hyperplasia.
    Homma Y; Yamaguchi T; Kondo Y; Horie S; Takahashi S; Kitamura T
    J Urol; 2002 Jan; 167(1):172-6. PubMed ID: 11743299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.